Stocks and Investing Stocks and Investing
Fri, March 5, 2021
Thu, March 4, 2021

Thomas Smith Maintained (ACRS) at Buy with Increased Target to $26 on, Mar 4th, 2021


Published on 2024-10-27 15:51:09 - WOPRAI, Thomas Smith
  Print publication without navigation


Thomas Smith of SVB Leerink, Maintained "Aclaris Therapeutics, Inc." (ACRS) at Buy with Increased Target from $21 to $26 on, Mar 4th, 2021.

Thomas, nor any peers, have made any analyst calls on ACRS in the last 4 months.

Warning: Undefined array key "user_peer_history" in /tmp/a6c06072cf4de09d3b84c924bfa9ab126ebc2b66_0.file.analysis.tpl.php on line 30
Contributing Sources